Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genxone has the GF Score of 68, which implies that the company
might have
Poor future performance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Genxone
might have
Poor future performance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Genxone (WAR:GX1) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Genxone GF Score Related Terms
WAR:GX1 vs VRTX, REGN, RVMD: GF Score Comparison
For the Biotechnology subindustry, Genxone's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genxone GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genxone's GF Score distribution charts can be found below:
* The bar in red indicates where Genxone's GF Score falls into.
Genxone (WAR:GX1) has a GF Score of 68 as of Jul. 30, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Genxone and its competitors. This is 134% above median its historical median of 29.00. Over the past decade, Genxone's GF Score has ranged from 4.00 to 75.00.
Is Genxone's GF Score too high?
Genxone's current GF Score of 68 is 134% above median its 10-year median of 29.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 75.00. Overall, Genxone has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genxone's GF Score compare to VRTX and REGN?
Genxone's GF Score of 68 can be compared against companies in the Biotechnology industry. Historically, Genxone's own GF Score has ranged from 4.00 to 75.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Genxone and its competitors. Genxone's current GF Score is 68, which is 134% above median its own 10-year median of 29.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genxone stock overvalued right now?
Based on GuruFocus' analysis, Genxone (WAR:GX1) is currently considered Modestly Undervalued. The stock's GF Value™ is zł6.48, compared to a current price of zł5.72 — trading 11.7% below its estimated fair value. The current GF Score is 68, which is 134% above median its 10-year median of 29.00. Genxone's overall GF Score™ is 68/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Genxone (WAR:GX1), the current GF Score is 68 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genxone (WAR:GX1) Overvalued in 2026?
Based on GuruFocus' analysis, Genxone stock appears to be undervalued.
The current stock price of zł5.72 is trading 11.7% below its estimated GF Value™ of zł6.48.
GuruFocus considers Genxone to be Modestly Undervalued.
Key valuation signals for WAR:GX1:
GF Score: 68 (134% above median its 10-year median of 29.00)
GF Value™: zł6.48 vs. price of zł5.72 (11.7% below fair value)
No single metric tells the full story. See the WAR:GX1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genxone SA is a biotechnology company that applies nanopore sequencing technology (third-generation of NGS) to many areas of science and business, including genetic diagnostics and the food industry. It specializes in developing new products and solutions based on the latest technologies of nucleic acid sequencing. The company's services include NANOPORE SEQUENCING that includes Whole Genome Sequencing, Bespoke Analysis, Metagenome Sequencing, Bioinformatic Analysis, 16S and/or ITS Gene Sequencing, and RNA Sequencing; and DIAGNOSTIC TESTS that includes Gastrointestinal Infections Panel, Respiratory Infections Panel, Urogenital Infection Panel, and Nervous System Infection Panel.
68GF Score
Get the complete analysis for WAR:GX1
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:GX1 has been successfully added to your 
